clinical trial · NCT04483531
Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis
Albireo·—·approved for marketing
Progressive Familial Intrahepatic CholestasisOdevixibat
brief summary
To provide treatment access to patients with PFIC in the US who have pruritus and elevated serum bile acids and who are not able to enroll in A4250-008 (PEDFIC2) for the following reasons: 1) Do not meet eligibility criteria for PEDFIC 2; 2) Are not able to get to a PEDFIC 2 site for geographical reasons, and 3) Do meet the eligibility criteria for PEDFIC 2 after recruitment has been completed
started
—
primary completion
—
completion
—
last updated
Mar 7, 2024
detailed description
Eligible patients will be enrolled into this expanded-access program and treated with an oral dose of 120 μg/kg/day of odevixibat and evaluated on an ongoing basis.
official title
Odevixibat (A4250) for the Treatment of Progressive Familial Intrahepatic Cholestasis (Expanded Access Program)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol